XA

Beyond Air, Inc.

XAIRHealthcareNASDAQ

Medical Devices · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$7.7M
+107.3% YoY
Net Income
-$33.2M
+28.7% YoY
EBITDA
-$27.2M
+35.1% YoY
Free Cash Flow
-$14.1M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 RSI OverboughtRSI 98.1, above 70, stock may be overbought
Jul 13 RSI OverboughtRSI 88.3, above 70, stock may be overbought
About Beyond Air, Inc.

Part of the healthcare sector, Beyond Air, Inc. (XAIR) is listed under Medical Devices. The $4.3M market capitalization puts XAIR squarely in micro-cap range for its industry. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments.

Where XAIR stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, XAIR finished 603.66% above its 150-day moving average ($0.82) and 419.82% above its 200-day moving average ($1.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is XAIR overbought or oversold?

At the July 15, 2026 close, XAIR's RSI(14) was 98.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$4.3M
Fwd P/E-3.55
EPS$-80.20
Beta0.22
52W Change-91.3%
ROE-334.1%
Analysis

The company holds $11.6M in cash, though total debt stands at $23.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$14.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -334.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.

With a beta below 0.7, Beyond Air, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Beyond Air, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
XAIR: Beyond Air, Inc. Technical Analysis (200-Day MA, RSI, MACD) | Scanance